Sofinnova Investments 13F annual report
Sofinnova Investments is an investment fund managing more than $1.59 trillion ran by Nathalie Auber. There are currently 72 companies in Mrs. Auber’s portfolio. The largest investments include Natera Inc and Vera Therapeutics Inc, together worth $269 billion.
$1.59 trillion Assets Under Management (AUM)
As of 8th August 2024, Sofinnova Investments’s top holding is 1,550,280 shares of Natera Inc currently worth over $168 billion and making up 10.6% of the portfolio value.
Relative to the number of outstanding shares of Natera Inc, Sofinnova Investments owns more than approximately 0.1% of the company.
In addition, the fund holds 2,793,987 shares of Vera Therapeutics Inc worth $101 billion.
The third-largest holding is Ascendis Pharma A/S worth $100 billion and the next is Novo-nordisk A S worth $92.7 billion, with 649,541 shares owned.
Currently, Sofinnova Investments's portfolio is worth at least $1.59 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Sofinnova Investments
The Sofinnova Investments office and employees reside in Menlo Park, California. According to the last 13-F report filed with the SEC, Nathalie Auber serves as the Attorney-in-Fact at Sofinnova Investments.
Recent trades
In the most recent 13F filing, Sofinnova Investments revealed that it had opened a new position in
Edwards Lifesciences Corp and bought 724,225 shares worth $66.9 billion.
This means they effectively own approximately 0.1% of the company.
Edwards Lifesciences Corp makes up
5.6%
of the fund's Health Care sector allocation and has decreased its share price by 16.7% in the past year.
The investment fund also strengthened its position in Novo-nordisk A S by buying
37,657 additional shares.
This makes their stake in Novo-nordisk A S total 649,541 shares worth $92.7 billion.
On the other hand, there are companies that Sofinnova Investments is getting rid of from its portfolio.
Sofinnova Investments closed its position in Merck & Co Inc on 15th August 2024.
It sold the previously owned 651,299 shares for $85.9 billion.
Nathalie Auber also disclosed a decreased stake in Ascendis Pharma A/S by approximately 0.1%.
This leaves the value of the investment at $100 billion and 734,284 shares.
One of the largest hedge funds
The two most similar investment funds to Sofinnova Investments are Sageworth Trust Co and Empire Life Investments. They manage $1.59 trillion and $1.59 trillion respectively.
Nathalie Auber investment strategy
Sofinnova Investments’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 75.1% of
the total portfolio value.
The fund focuses on investments in the United States as
62.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
21% of the total holdings value.
On the other hand, small-cap stocks make up only 8.3% of the portfolio.
The average market cap of the portfolio companies is close to $15.3 billion.
The complete list of Sofinnova Investments trades based on 13F SEC filings
These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Natera Inc |
No change
1,550,280
|
$167,879,821,000 | 10.58% |
| Vera Therapeutics Inc |
No change
2,793,987
|
$101,086,450,000 | 6.37% |
| Ascendis Pharma A/S |
2.62%
734,284
|
$100,141,652,000 | 6.31% |
| Novo-nordisk A S |
6.15%
649,541
|
$92,715,482,000 | 5.84% |
| Merck & Co Inc |
Closed
651,299
|
$85,938,903,000 | |
| Incyte Corp. |
Closed
1,327,178
|
$75,609,331,000 | |
| Edwards Lifesciences Corp |
Opened
724,225
|
$66,896,663,000 | 4.22% |
| Stryker Corp. |
Opened
193,084
|
$65,696,831,000 | 4.14% |
| Astrazeneca plc |
34.31%
801,417
|
$62,502,512,000 | 3.94% |
| Argenx Se |
Closed
149,300
|
$58,782,396,000 | |
| Dyne Therapeutics, Inc. |
16.06%
1,625,703
|
$57,371,059,000 | 3.62% |
| Align Technology, Inc. |
128.87%
218,524
|
$52,758,249,000 | 3.32% |
| Inhibrx, Inc. |
Closed
1,302,645
|
$45,540,469,000 | |
| Rapport Therapeutics Inc |
Opened
1,951,562
|
$45,393,332,000 | 2.86% |
| Syndax Pharmaceuticals Inc |
33.89%
2,153,669
|
$44,214,825,000 | 2.79% |
| Elanco Animal Health Inc |
12.08%
2,864,250
|
$41,331,128,000 | 2.60% |
| IDEAYA Biosciences, Inc. |
47.33%
1,151,528
|
$40,430,148,000 | 2.55% |
| Intuitive Surgical Inc |
38.09%
87,217
|
$38,798,482,000 | 2.44% |
| Alnylam Pharmaceuticals Inc |
43.57%
147,929
|
$35,946,747,000 | 2.27% |
| TG Therapeutics Inc |
6.23%
1,861,277
|
$33,112,118,000 | 2.09% |
| Arrivent Biopharma Inc |
No change
1,696,752
|
$31,474,750,000 | 1.98% |
| Idexx Labs Inc |
15.10%
63,862
|
$31,113,566,000 | 1.96% |
| Sarepta Therapeutics Inc |
13.91%
195,852
|
$30,944,616,000 | 1.95% |
| Y-Mabs Therapeutics Inc |
No change
2,194,278
|
$26,506,878,000 | 1.67% |
| Axsome Therapeutics Inc |
Opened
310,198
|
$24,970,939,000 | 1.57% |
| Cogent Biosciences, Inc. |
15.52%
2,773,286
|
$23,378,801,000 | 1.47% |
| Soleno Therapeutics Inc |
267.67%
554,359
|
$22,617,847,000 | 1.43% |
| Silk Rd Med Inc |
Closed
1,189,024
|
$21,782,920,000 | |
| Savara Inc |
128.31%
5,358,918
|
$21,596,440,000 | 1.36% |
| Celldex Therapeutics Inc. |
31.69%
547,707
|
$20,270,636,000 | 1.28% |
| Roivant Sciences Ltd |
86.52%
1,868,412
|
$19,749,115,000 | 1.24% |
| Establishment Labs Holdings Inc |
204.08%
429,244
|
$19,504,847,000 | 1.23% |
| Inozyme Pharma, Inc. |
No change
4,280,308
|
$19,090,174,000 | 1.20% |
| Revolution Medicines Inc |
Opened
455,099
|
$17,662,392,000 | 1.11% |
| Kura Oncology Inc |
64.41%
825,243
|
$16,991,753,000 | 1.07% |
| Insmed Inc |
Opened
227,747
|
$15,259,049,000 | 0.96% |
| Boston Scientific Corp. |
51.65%
171,080
|
$13,174,871,000 | 0.83% |
| Madrigal Pharmaceuticals Inc |
133.42%
44,417
|
$12,443,867,000 | 0.78% |
| Insulet Corporation |
72.31%
60,967
|
$12,303,141,000 | 0.78% |
| Shockwave Med Inc |
Closed
35,000
|
$11,397,050,000 | |
| Pharvaris N V |
2.88%
601,534
|
$11,308,839,000 | 0.71% |
| Axonics Inc |
0.74%
150,490
|
$10,117,443,000 | 0.64% |
| Immatics N.v |
63.18%
796,704
|
$9,257,700,000 | 0.58% |
| Cabaletta Bio Inc |
183.98%
1,220,400
|
$9,128,592,000 | 0.58% |
| Pepgen Inc |
11.42%
561,128
|
$8,955,603,000 | 0.56% |
| Edgewise Therapeutics Inc |
Opened
475,691
|
$8,567,195,000 | 0.54% |
| Immunome, Inc. |
10.31%
655,680
|
$7,933,728,000 | 0.50% |
| Exact Sciences Corp. |
20.77%
181,828
|
$7,682,233,000 | 0.48% |
| Inari Med Inc |
1,425.43%
155,838
|
$7,503,600,000 | 0.47% |
| Dexcom Inc |
Opened
61,494
|
$6,972,190,000 | 0.44% |
| Inhibrx Biosciences Inc |
Opened
463,315
|
$6,565,174,000 | 0.41% |
| Achieve Life Sciences Inc. |
8.55%
1,388,372
|
$6,525,348,000 | 0.41% |
| Waters Corp. |
Opened
21,804
|
$6,325,776,000 | 0.40% |
| Aerovate Therapeutics Inc |
No change
3,758,686
|
$6,239,419,000 | 0.39% |
| 4D Molecular Therapeutics Inc. |
36.82%
271,155
|
$5,691,543,000 | 0.36% |
| Marinus Pharmaceuticals Inc |
196.32%
4,151,576
|
$4,857,344,000 | 0.31% |
| Nextcure Inc |
No change
2,671,856
|
$4,248,251,000 | 0.27% |
| Erasca Inc |
Opened
1,699,528
|
$4,010,886,000 | 0.25% |
| Phibro Animal Health Corp. |
Opened
237,009
|
$3,974,641,000 | 0.25% |
| Baxter International Inc. |
488.84%
117,769
|
$3,939,373,000 | 0.25% |
| Fusion Pharmaceuticals Inc. |
Closed
157,172
|
$3,350,907,000 | |
| Avantor, Inc. |
39.32%
141,045
|
$2,990,154,000 | 0.19% |
| Teleflex Incorporated |
12.41%
13,649
|
$2,870,794,000 | 0.18% |
| Masimo Corp |
0.80%
20,161
|
$2,539,076,000 | 0.16% |
| Cooper Cos Inc |
Closed
21,236
|
$2,154,605,000 | |
| Bolt Biotherapeutics Inc |
No change
2,754,437
|
$2,065,828,000 | 0.13% |
| Inspire Med Sys Inc |
23.47%
10,000
|
$1,338,300,000 | 0.08% |
| Disc Medicine Inc |
373.93%
29,256
|
$1,318,568,000 | 0.08% |
| Perspective Therapeutics Inc |
Opened
132,089
|
$1,316,927,000 | 0.08% |
| Zimmer Biomet Holdings Inc |
Opened
10,630
|
$1,153,674,000 | 0.07% |
| LivaNova PLC |
0.71%
20,602
|
$1,129,402,000 | 0.07% |
| Immatics N.v |
Opened
348,731
|
$932,855,000 | 0.06% |
| NuCana plc |
Closed
4,708,614
|
$1,224,240,000 | |
| Avidity Biosciences, Inc. |
Opened
21,425
|
$875,211,000 | 0.06% |
| Ikena Oncology Inc |
No change
382,616
|
$631,316,000 | 0.04% |
| Amylyx Pharmaceuticals Inc |
2.29%
299,691
|
$569,413,000 | 0.04% |
| Astria Therapeutics Inc |
Opened
60,692
|
$552,297,000 | 0.03% |
| Perspective Therapeutics Inc |
Closed
430,105
|
$511,825,000 | |
| PDS Biotechnology Corporation |
No change
142,635
|
$417,921,000 | 0.03% |
| Pulmonx Corp |
Opened
60,246
|
$381,960,000 | 0.02% |
| Kyverna Therapeutics Inc |
378.50%
47,850
|
$358,875,000 | 0.02% |
| Structure Therapeutics Inc |
2.08%
8,915
|
$350,092,000 | 0.02% |
| Mirum Pharmaceuticals Inc |
Closed
3,012
|
$75,661,000 | |
| No transactions found | |||
| Showing first 500 out of 83 holdings | |||
Hedge funds similar to Sofinnova Investments
- Concourse Financial Group Securities, Inc
- Investmentaktiengesellschaft Fuer Langfristige Investoren Tgv
- Cryder Capital Partners LL.P.
- Empirical Finance
- Wilkinson Global Asset Management
- Alta Capital Management
- Sigma Investment Counselors Inc
- Sageworth Trust Co
- Empire Life Investments
- North Reef Capital Management L.P.
- Tsg Consumer Partners L.P.
- Jb Capital
- Graham Capital Management, L.P.
- Acropolis Investment Management